Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medtronic, a medical device company, has received regulatory approval from the Japanese Ministry of Health, Labor and Welfare for the Talent thoracic stent graft, a lifesaving technology that allows more patients to benefit from a minimally-invasive treatment for certain types of aneurysms of the descending thoracic aorta.
Subscribe to our email newsletter
The Japanese Ministry of Health, Labor and Welfare has also granted approval for the Reliant stent graft balloon catheter, which is used in abdominal and thoracic endovascular procedures to facilitate endograft modeling and fixation to the vessel wall.
Medtronic plans to launch the Talent thoracic stent graft and the Reliant stent graft balloon catheter in Japan after reimbursement approval.
Tony Semedo, vice president of the cardiovascular business at Medtronic, said: “Japan is a high-priority market for Medtronic. Pending the requisite regulatory and reimbursement approvals, in the years ahead, we intend to follow the Talent thoracic stent graft with many other aortic repair technologies from our extensive portfolio and pipeline to extend the option of minimally-invasive treatment to even more patients.”